Grifols (NASDAQ:GRFS)'s stock had its "overweight" rating reaffirmed by equities researchers at Barclays in a report released on Friday, The Fly reports.
Several other equities research analysts have also recently issued reports on the stock. Citigroup upgraded shares of Grifols from a "sell" rating to a "neutral" rating in a research report on Thursday, October 1st. Berenberg Bank reissued a "buy" rating on shares of Grifols in a report on Friday, October 30th. Zacks Investment Research upgraded Grifols from a "hold" rating to a "buy" rating and set a $22.00 target price for the company in a research report on Thursday. Morgan Stanley restated an "overweight" rating on shares of Grifols in a research report on Wednesday, January 13th. Finally, Credit Suisse Group reaffirmed a "neutral" rating on shares of Grifols in a research note on Wednesday. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Grifols has an average rating of "Hold" and an average price target of $22.00.
Shares of GRFS traded down $0.18 on Friday, reaching $19.15. The company's stock had a trading volume of 50,218 shares, compared to its average volume of 792,357. The stock's 50 day simple moving average is $18.96 and its two-hundred day simple moving average is $18.16. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.93 and a quick ratio of 1.33. The stock has a market capitalization of $13.17 billion, a P/E ratio of 17.10, a PEG ratio of 1.30 and a beta of 0.59. Grifols has a 12-month low of $13.40 and a 12-month high of $25.73.
Grifols (NASDAQ:GRFS) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.34 by $0.02. Grifols had a net margin of 12.79% and a return on equity of 10.65%. The business had revenue of $1.52 billion for the quarter, compared to the consensus estimate of $1.58 billion. Analysts expect that Grifols will post 1.36 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of the company. First Trust Advisors LP grew its stake in Grifols by 20.2% during the 3rd quarter. First Trust Advisors LP now owns 3,749,065 shares of the biotechnology company's stock worth $65,046,000 after buying an additional 629,650 shares during the last quarter. Hengistbury Investment Partners LLP purchased a new stake in shares of Grifols during the third quarter worth about $38,811,000. JPMorgan Chase & Co. increased its holdings in shares of Grifols by 406.3% during the third quarter. JPMorgan Chase & Co. now owns 1,199,799 shares of the biotechnology company's stock valued at $20,169,000 after acquiring an additional 962,838 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Grifols by 25.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,117,796 shares of the biotechnology company's stock valued at $19,394,000 after purchasing an additional 224,126 shares during the last quarter. Finally, Todd Asset Management LLC raised its position in shares of Grifols by 1.1% in the 3rd quarter. Todd Asset Management LLC now owns 793,651 shares of the biotechnology company's stock valued at $13,770,000 after purchasing an additional 8,438 shares during the last quarter. 15.15% of the stock is owned by hedge funds and other institutional investors.
Grifols Company Profile
Grifols, SA develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Featured Story: Dual Listing What You Need to Know
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Top Ten Brokerages You Can Trust
There are more than 500 brokerages and research houses that hire analysts to issue ratings and recommendations. Collectively, these brokerages and their analysts publish approximately 250,000 ratings each year. Every trading day, there are nearly 700 reports and recommendations that are released to the public. To say that it's difficult to separate the signal from the noise when interpreting this data would be an understatement.
MarketBeat has developed a system to track each brokerage and research house's stock recommendations and score them based on their past performance. If Goldman Sachs predicted that Apple's stock price would hit $150.00 on a specific date, how accurate were they? If Bank of America issued a "strong-buy" rating on a stock, how did that stock perform compared to the broader market over the following twelve months? This tracking system has been applied to the 1,000,000+ ratings that MarketBeat has tracked during the last ten years to identify which brokerages you can really trust (and which you can safely ignore).
This slide show lists the 10 brokerages who have issued the most accurate analyst recommendations over the past several years, as measured by the performance of their "buy" ratings and the accuracy of their price targets.
View the "Top Ten Brokerages You Can Trust".